These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 21038378)

  • 1. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Atkinson L; Elfring GL; Reha A; Miller LL
    Muscle Nerve; 2010 Dec; 42(6):966-74. PubMed ID: 21038378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL
    Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence JM; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz S
    Muscle Nerve; 2013 Sep; 48(3):343-56. PubMed ID: 23681930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.
    Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H
    J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
    Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ;
    Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal community walking activity in Duchenne muscular dystrophy.
    Fowler EG; Staudt LA; Heberer KR; Sienko SE; Buckon CE; Bagley AM; Sussman MD; McDonald CM
    Muscle Nerve; 2018 Mar; 57(3):401-406. PubMed ID: 28692198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
    Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six minute walk distance in healthy subjects aged 55-75 years.
    Camarri B; Eastwood PR; Cecins NM; Thompson PJ; Jenkins S
    Respir Med; 2006 Apr; 100(4):658-65. PubMed ID: 16229997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-minute walk test in children with chronic conditions.
    Hassan J; van der Net J; Helders PJ; Prakken BJ; Takken T
    Br J Sports Med; 2010 Mar; 44(4):270-4. PubMed ID: 18487250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
    Biggar WD; Harris VA; Eliasoph L; Alman B
    Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
    Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pain, osteopenia and body composition of 22 patients with Duchenne muscular dystrophy: a descriptive study].
    Douvillez B; Braillon P; Hodgkinson I; Berard C
    Ann Readapt Med Phys; 2005 Nov; 48(8):616-22. PubMed ID: 16023755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
    Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J;
    PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of caregiving on women in families with Duchenne/Becker muscular dystrophy.
    Kenneson A; Bobo JK
    Health Soc Care Community; 2010 Sep; 18(5):520-8. PubMed ID: 20561071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophies.
    Soelaeman RH; Smith MG; Sahay K; Tilford JM; Goodenough D; Paramsothy P; Ouyang L; Oleszek J; Grosse SD
    Muscle Nerve; 2021 Dec; 64(6):717-725. PubMed ID: 34605048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gait assessment in children with duchenne muscular dystrophy during long-distance walking.
    Ganea R; Jeannet PY; Paraschiv-Ionescu A; Goemans NM; Piot C; Van den Hauwe M; Aminian K
    J Child Neurol; 2012 Jan; 27(1):30-8. PubMed ID: 21765150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of growth in ambulatory males with Duchenne muscular dystrophy.
    West NA; Yang ML; Weitzenkamp DA; Andrews J; Meaney FJ; Oleszek J; Miller LA; Matthews D; DiGuiseppi C
    J Pediatr; 2013 Dec; 163(6):1759-1763.e1. PubMed ID: 24103921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gait pattern in Duchenne muscular dystrophy.
    D'Angelo MG; Berti M; Piccinini L; Romei M; Guglieri M; Bonato S; Degrate A; Turconi AC; Bresolin N
    Gait Posture; 2009 Jan; 29(1):36-41. PubMed ID: 18656361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.